Table 1.
Demographics and disease characteristics of patients included in overall survival models postimputation
| Train | Val1 | Val2 | Val3 | Val4 | P value | |
|---|---|---|---|---|---|---|
| Dataset | ||||||
| N0147 | 2318 | 943 | 0 | 0 | 0 | |
| PETACC-3 | 698 | 556 | 0 | 0 | 0 | |
| CRCSC | 0 | 0 | 368 | 189 | 52 | |
| CCFR | 0 | 0 | 473 | 401 | 730 | |
| Oslo | 0 | 0 | 108 | 490 | 0 | |
| Total | 3016 | 1499 | 949 | 1080 | 782 | |
| TNM staging | <0.001 | |||||
| IIA | 318 (10%) | 0 | 336 (35%) | 756 (70%) | 320 (40%) | |
| IIB/IIC | 77 (3%) | 0 | 61 (7%) | 78 (7%) | 22 (3%) | |
| IIIA | 292 (10%) | 170 (11%) | 50 (5%) | 11 (1%) | 59 (8%) | |
| IIIB | 1795 (59%) | 1034 (69%) | 359 (38%) | 147 (14%) | 342 (44%) | |
| IIIC | 534 (18%) | 295 (20%) | 143 (15%) | 88 (8%) | 39 (5%) | |
| Clinicopathological | ||||||
| Age in years | <0.001 | |||||
| Median (range) | 59 (19–85) | 59 (21–86) | 62 (22–96) | 70 (24–94) | NA | |
| Sex | 0.004 | |||||
| Female | 1374 (46%) | 694 (46%) | 465 (46%) | 551 (51%) | NA | |
| Male | 1642 (54%) | 805 (54%) | 484 (54%) | 529 (49%) | NA | |
| Lymph nodes assessed | <0.001 | |||||
| Median (IQR) | 17 (12–23) | 16 (11–22) | 11 (6–19) | 10 (6–21) | NA | |
| Tumor grade | <0.001 | |||||
| Low/medium | 2382 (79%) | 1212 (81%) | 811 (84%) | 981 (91%) | NA | |
| High | 634 (21%) | 287 (19%) | 148 (16%) | 99 (9%) | NA | |
| Primary tumor site | <0.001 | |||||
| Right colon | 1464 (49%) | 688 (46%) | 482 (51%) | 647 (60%) | NA | |
| Left colon | 1552 (51%) | 811 (54%) | 467 (49%) | 433 (40%) | NA | |
| Adjuvant chemotherapy | <0.001 | |||||
| None | 0 | 0 | 0 | 1080 (100%) | NA | |
| 5FU/capecitabine | 359 (12%) | 274 (18%) | 852 (90%) | 0 | NA | |
| FOLFIRIa | 415 (14%) | 313 (21%) | 4 (1%) | 0 | NA | |
| FOLFIRIa/cetuximab | 32 (1%) | 9 (1%) | 0 | 0 | NA | |
| FOLFOXb | 1228 (41%) | 550 (37%) | 93 (9%) | 0 | NA | |
| FOLFOXb/cetuximab | 982 (32%) | 353 (23%) | 0 | 0 | NA | |
| Molecular | <0.001 | |||||
| MSI status | ||||||
| MSI-high | 383 (13%) | 183 (12%) | 182 (19%) | 276 (26%) | 135 (17%) | |
| MSS/MSI-low | 2633 (87%) | 1316 (88%) | 767 (81%) | 804 (74%) | 647 (83%) | |
| BRAF V600E status | <0.001 | |||||
| Mutated | 345 (11%) | 162 (11%) | 124 (13%) | 205 (19%) | 102 (13%) | |
| Wild-type | 2671 (89%) | 1337 (89%) | 825 (87%) | 875 (81%) | 680 (87%) | |
| KRAS codons 12/13 status | <0.001 | |||||
| Mutated | 1078 (36%) | 566 (38%) | 349 (37%) | 331 (31%) | 239 (31%) | |
| Wild-type | 1938 (64%) | 933 (62%) | 600 (63%) | 749 (69%) | 543 (69%) | |
a
Infusional 5FU with irinotecan.
b
Infusional 5FU with oxaliplatin.
NA, not applicable.